TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2021
Historique:
pubmed: 14 2 2021
medline: 14 9 2021
entrez: 13 2 2021
Statut: ppublish

Résumé

Transactive response DNA-binding protein of 43 kDa (TDP-43) is associated with memory impairment and overall cognitive decline. It is unclear how TDP-43 contributes to the rate of clinical decline. To determine whether cross-sectional and longitudinal cognitive and functional decline are associated with anatomical distribution of TDP-43 in the brain. Longitudinal clinical-neuropathologic autopsy cohort study of 385 initially cognitively normal/mildly impaired older adults prospectively followed until death. We investigated how TDP-43, amyloid-β (Aβ), tau neurofibrillary tangles (NFT), Lewy body disease (LBD), age, sex, and genetics are associated with clinical scores and rates of their longitudinal decline. Of 385 participants, 260 (68%) had no TDP-43, 32 (8%) had TDP-43 limited to amygdala, and 93 (24%) had TDP-43 in the hippocampus and beyond. Higher TDP-43 and Braak NFT stages independently were associated with faster decline in global cognition, functional performance measured by Clinical Dementia Rating scale, and naming and episodic memory, whereas older age was associated with slower rate of cognitive, psychiatric, and functional decline. Cross-sectionally the following associations were found: higher TDP-43 and Braak NFT - worse performance; higher Aβ burden - worse global cognition, more behavioral changes, the latter also with higher LBD; older age - worse naming, lower frequency of behavioral changes; female sex - more impaired naming and better preserved episodic memory. There were no genetic associations. The association of TDP-43 distribution with decline in cognitive and functional performance suggests that TDP-43 is playing a role in the clinical progression to dementia. Further characterization of clinical features associated with TDP-43 can facilitate establishment of antemortem diagnosis.

Sections du résumé

BACKGROUND
Transactive response DNA-binding protein of 43 kDa (TDP-43) is associated with memory impairment and overall cognitive decline. It is unclear how TDP-43 contributes to the rate of clinical decline.
OBJECTIVE
To determine whether cross-sectional and longitudinal cognitive and functional decline are associated with anatomical distribution of TDP-43 in the brain.
METHODS
Longitudinal clinical-neuropathologic autopsy cohort study of 385 initially cognitively normal/mildly impaired older adults prospectively followed until death. We investigated how TDP-43, amyloid-β (Aβ), tau neurofibrillary tangles (NFT), Lewy body disease (LBD), age, sex, and genetics are associated with clinical scores and rates of their longitudinal decline.
RESULTS
Of 385 participants, 260 (68%) had no TDP-43, 32 (8%) had TDP-43 limited to amygdala, and 93 (24%) had TDP-43 in the hippocampus and beyond. Higher TDP-43 and Braak NFT stages independently were associated with faster decline in global cognition, functional performance measured by Clinical Dementia Rating scale, and naming and episodic memory, whereas older age was associated with slower rate of cognitive, psychiatric, and functional decline. Cross-sectionally the following associations were found: higher TDP-43 and Braak NFT - worse performance; higher Aβ burden - worse global cognition, more behavioral changes, the latter also with higher LBD; older age - worse naming, lower frequency of behavioral changes; female sex - more impaired naming and better preserved episodic memory. There were no genetic associations.
CONCLUSION
The association of TDP-43 distribution with decline in cognitive and functional performance suggests that TDP-43 is playing a role in the clinical progression to dementia. Further characterization of clinical features associated with TDP-43 can facilitate establishment of antemortem diagnosis.

Identifiants

pubmed: 33579840
pii: JAD201166
doi: 10.3233/JAD-201166
pmc: PMC8020877
mid: NIHMS1680278
doi:

Substances chimiques

APP protein, human 0
Amyloid beta-Protein Precursor 0
DNA-Binding Proteins 0
MAPT protein, human 0
TARDBP protein, human 0
tau Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

683-693

Subventions

Organisme : NIA NIH HHS
ID : P30 AG062677
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG037491
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG006786
Pays : United States

Références

J Alzheimers Dis. 2015;50(1):283-95
pubmed: 26682680
JAMA Neurol. 2013 Nov;70(11):1418-24
pubmed: 24080705
Brain. 2019 Jun 1;142(6):1503-1527
pubmed: 31039256
Neuroepidemiology. 2008;30(1):58-69
pubmed: 18259084
Neurology. 2008 May 6;70(19 Pt 2):1850-7
pubmed: 18401022
Brain. 2011 Dec;134(Pt 12):3708-15
pubmed: 22120149
Lancet Neurol. 2017 Nov;16(11):917-924
pubmed: 28919059
J Alzheimers Dis. 2018;66(1):115-126
pubmed: 30223398
J Neurosci Methods. 1994 Aug;53(2):125-7
pubmed: 7823614
J Int Neuropsychol Soc. 2021 Mar;27(3):211-226
pubmed: 32815494
Alzheimers Dement. 2019 May;15(5):675-685
pubmed: 30853465
Alzheimers Dement. 2012 Jan;8(1):1-13
pubmed: 22265587
J Int Neuropsychol Soc. 2015 Feb;21(2):95-104
pubmed: 25665170
Neuropathol Appl Neurobiol. 2020 Dec;46(7):722-734
pubmed: 32896913
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Neurobiol Aging. 2020 Aug;92:92-97
pubmed: 32408057
Neurology. 1991 Apr;41(4):479-86
pubmed: 2011243
J Gerontol B Psychol Sci Soc Sci. 2008 Jul;63(4):P235-P240
pubmed: 18689765
Brain. 2020 Dec 1;143(12):3842-3849
pubmed: 33188391
Brain. 2020 Dec 5;143(11):3463-3476
pubmed: 33150361
Neurology. 2020 Jul 7;95(1):e23-e34
pubmed: 32518145
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Acta Neuropathol. 2016 Apr;131(4):571-85
pubmed: 26810071
Neurology. 2017 Feb 14;88(7):653-660
pubmed: 28087828
Neuropsychology. 2016 Jul;30(5):591-9
pubmed: 27111293
Neurobiol Aging. 2019 May;77:26-36
pubmed: 30776649
Br J Psychiatry. 1982 Jun;140:566-72
pubmed: 7104545
J Alzheimers Dis. 2020;73(4):1511-1523
pubmed: 31929165
Brain. 2019 Nov 1;142(11):3621-3635
pubmed: 31562527
J Neurosci. 2009 Oct 14;29(41):12711-6
pubmed: 19828780
Brain Pathol. 2010 Jan;20(1):66-79
pubmed: 19021630
Acta Neuropathol. 2014;127(6):811-24
pubmed: 24659241
Alzheimer Dis Assoc Disord. 2007 Jul-Sep;21(3):249-58
pubmed: 17804958
Acta Neuropathol. 2018 Sep;136(3):377-388
pubmed: 29916037
Nat Rev Neurosci. 2009 Apr;10(4):272-82
pubmed: 19300446
Neurology. 2016 Nov 1;87(18):1916-1924
pubmed: 27708128
Acta Neuropathol Commun. 2019 Jun 7;7(1):91
pubmed: 31174609
Brain Lang. 1980 Mar;9(2):255-68
pubmed: 7363069
Brain. 2017 Mar 1;140(3):804-812
pubmed: 28082297
J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9
pubmed: 11001602
Acta Neuropathol. 2014 Mar;127(3):441-50
pubmed: 24240737
Science. 2006 Oct 6;314(5796):130-3
pubmed: 17023659

Auteurs

Marina Buciuc (M)

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Nirubol Tosakulwong (N)

Department of Health Science Research, Mayo Clinic, Rochester, MN, USA.

Mary M Machulda (MM)

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.

Jennifer L Whitwell (JL)

Department of Radiology, Mayo Clinic, Rochester, MN, USA.

Stephen D Weigand (SD)

Department of Health Science Research, Mayo Clinic, Rochester, MN, USA.

Melissa E Murray (ME)

Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.

R Ross Reichard (RR)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Joseph E Parisi (JE)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Dennis W Dickson (DW)

Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.

Bradley F Boeve (BF)

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

David S Knopman (DS)

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Ronald C Petersen (RC)

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Keith A Josephs (KA)

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH